期刊文献+

美国罕见病用药的专业药房销售模式研究 被引量:5

Research on Orphan Drug Sales Model of Professional Pharmacy in U.S.
下载PDF
导出
摘要 目的探索我国罕见病药品的销售模式,促进罕见病患者用药可及性。方法采取文献研究方法对美国罕见病用药的专业药房销售模式进行分析,借鉴其成功经验,提出选择我国罕见病药品销售模式的思路。结果针对罕见病用药的不规则低需求、高用药生理和心理需求、高个性化用药和及时性用药需求及高价格、高购买成本的销售特点,美国的罕见病用药生产、流通企业采取与常见病药品不同的营销方式,如建立专门的信息服务平台,采取同步性销售、示范促销、人员促销、服务促销、靶向性专业化销售、邮件预订和靶向公关策略等营销方式。结论在我国的每个省份或者地级市确定专业药房和罕见病用药生产与储备目录,把顾客群靶向性定位于罕见病患者,与罕见病患者、医生、药品生产商、保险方联合起来,提高罕见病药品的可及性。 Objective To explore Chinese orphan drug sales model,to promote orphan drug availability.Methods U.S.orphan drug sales model of professional pharmacy was analyzed by the literature research method,drawing on its successful experience,made the selection idea for orphan drug sales mode in China.Results In allusion to the sales characteristics of orphan drug,such as irregular low demand,high physical and psychological needs medication,high personalized medicine,timeliness of drug demand,high prices and high purchase cost,the U.S.production,circulation and enterprises of orphan drug were adopt different marketing methods to common drugs such as the establishment of specialized information service platform,to synchronization of sales,sales demonstrations,staff promotions,service,promotions,targeting professional sales,mail order and public relations strategies targeted marketing.Conclusion In our country in each province or prefecture-level city,to determine the professional pharmacy and orphan drug production and reserves of the directory,to target customer base located in the rare patients,doctors,drug manufacturers,insurers together,to improve orphan drugs accessibility.
出处 《中国药事》 CAS 2011年第12期1238-1242,共5页 Chinese Pharmaceutical Affairs
基金 国家自然基金青年基金项目(编号70903025)
关键词 专业药房 罕见病 销售模式 罕见病用药 professional pharmacy rare disease sales model orphan drug
  • 相关文献

参考文献11

  • 1龚时薇,张亮,金肆,李琳琳.提高我国罕见病患者用药可及性的管理策略研究[J].中华医院管理杂志,2010,26(2):126-130. 被引量:7
  • 2Rowena N. Schwartz, Kirby J. Eng, Deborah A. Frieze, et al. NCCN Task Force Report: Specialty Pharmacy [J]. National Comprehensive Cancer Network, July 2010, 8 (4):1-11.
  • 3Suzanne Shelley. Rare Diseases and Orphan Drugs Lift Phar- ma Innovation [J]. Pharmaceutical Commerce, 2010.
  • 4Pamela Leigh Sauerwald. Changing the Channel: Develop- ments in US Specialty Pharmaceutical Distribution[J ]. Pharmaceutical Commerce, 2009.
  • 5Rita Shane. Management of chronic diseases in the 21st een tury: The emerging role of specialty pharmacies [J]. Am J Health-Syst Pharm., 2007, 64:2382-2385.
  • 6James A. Jorgenson. Specialty Pharmacy.- Status and Future Direction [J]. The American Journal of Pharmacy Benefits, 2010, 2 (6): 347-348.
  • 7Ben Corner. Specialty Pharmaceuticals: Shifting Specialties [J] . Medical Marketing and Media, 2010.
  • 8David A. Blaser, Andrea J. Lewtas, Maria M. Ousterhout. How to Define Specialty Pharmaceuticals-A Systematic Re view [J]. The American Journal of Pharmacy Benefits 2010, 2 (6): 371-380.
  • 9Sean D. Sullivan. The Promise of Specialty Pharmaceuticals: Are They Worth the Price?[J]. Journal of Managed Care Pharmacy, 2008, 14 (4) (Supplement): 3-6.
  • 10Sarah Collin. Specialty Pharmacy Management Will Become More Intense [J]. Managed Care, 2010, 19 (10): 20- 23.

二级参考文献12

  • 1蒋舒.提高药品可及性的政策选择——强制许可[J].经济论坛,2004(12):122-123. 被引量:9
  • 2乌日图,贺晓科.亟须建立国家短缺药物管理制度[J].中国卫生,2007(7):92-95. 被引量:2
  • 3方剑春.生产不足,需求增长-血液制品供货紧张拉响警报[N].中国医药报,2007-07-26.
  • 4No authors listed. Help is Available for Patients Suffering from Rare Diseases; More Than 300 Orphan Drugs in Development Pipeline[N]. US Fed News Service, Including US State News. 2008-01-24.
  • 5Carla Maria Teixeira de Barros, Ana Luisa Papoila. Therapeutic profile of orphan medicines[J]. Pharmacoepidemiology and Drug Safety, 2007,16 (4) : 435-440.
  • 6冯立中,鲁先红.合肥罕见病患者求生困难[N].健康报,2007-02-08(2).
  • 7熊金超.武汉两家5口人铊中毒医院急寻救命药[DB/DL].http://www.hb.xinhua.org/newseenter/2008-05/09/content_13205475.html.
  • 8邵建国.亚洲:“孤儿药”乐土[N].医药经济报,2007-05-14(A3).
  • 9Schieppati A, Henter JI, Daina E, et al. Why rare diseases are an important medical and social issue[J]. Lancet, 2008, 14371(9629) :2039-2041.
  • 10赵志刚,朱乐婷,王莉文.全国11省市42家医院临床应用药品供应短缺现状调研分析[J].中国医院药学杂志,2008,28(1):65-66. 被引量:33

共引文献6

同被引文献54

  • 1张辉,刘君玉,王丹.药品生命周期不同阶段的学术推广要点[J].中华医学信息导报,2006,21(12):17-17. 被引量:4
  • 2龚时薇,张敏,邓秀玲,何惠君,李燕,王祎.对我国罕见病与罕用药界定的思考[J].中国新药杂志,2006,15(15):1225-1229. 被引量:20
  • 3Poon EG,Keohane CA,Yoon CS,et al.Effect of bar-code technology on the safety of medication administration[J].N Engl J Med,2010,362(18):1698-1707.
  • 4The Orphan Drug Act[ EB/OL]. http://www, ecfr. gov!.
  • 5Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach S L, et al. Incentives for orphan drug research and development in the UnitedStates [ J ]. Orphanet Journal of RareDiseases, 2008, 3(3): 33.
  • 6Jyoti T. Navigating through orphan medicinal product regula- tionsin EU and US-Similarities and differences [ J ]. Regula- tory Toxicology and Pharmacology, 2015, 71 (1) : 63-67.
  • 7Hurwicz L. The design of mechanisms for resource allocation [ J ] . American Economic Review, 1973, 63 (63) : 1-30.
  • 8Haffner M E. Orphan Products: Origins,Progress, and Pros- pects [ J ]. Annual Review of Pharmacology, 1991,31 ( 31 ) : 603-620.
  • 9Drummond M F, Wilson D A, Panos K, et al. Assessing the economicchallenges posed by orphan drugs [ J ]. Interna- tional Journal of Technology Assessment in Health Care, 2007, 23 ( 1 ) : 36-42.
  • 10Blaser D A, Lewtas A J, Ousterhout M M. How To Define Specialty Pharmaceuticals:A Systematic Review[ J]. The A- merican Journal of Pharmacy Benefits, 2010, 2 ( 6 ) : 371-380.

引证文献5

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部